Sponsor
Brad Sherman
Representative · D-CA
Representative · D-CA
The bill aims to lower prescription prices and improve supply resilience by authorizing fair‑price setting, enforcement, forced licensing, and production actions — but it trades those near‑term consumer savings and access mechanisms against risks to innovation, manufacturer supply decisions, administrative burden, and potential legal and fiscal costs.
Patients (including Medicare and Medicaid beneficiaries) would pay lower out‑of‑pocket prices because an independent Commission and HHS-set 'fair prices' would limit retail and dispensing costs.
Hospitals, physicians, and other providers would face lower drug acquisition costs and more predictable pricing when furnishing drugs to eligible patients, improving health‑system finances.
Patients and hospitals would experience fewer shortages and more reliable access because the bill enables HHS and the President (via DPA actions and forced licenses) to boost domestic production and compel additional suppliers.
Manufacturers may reduce R&D investment or delay new drug development if price limits constrain returns, risking fewer future treatments and slower innovation.
Manufacturers could respond to price controls by restricting supply, raising list prices, or withdrawing products from the U.S., causing immediate access problems for patients and providers.
The bill concentrates discretionary power and creates substantial administrative complexity (Commission structure, HHS march‑in/license authority, rulemaking and revisions), producing legal uncertainty and potential delays in delivering price relief.
Based on analysis of 7 sections of legislative text.
Creates a federal commission to set binding annual "fair prices" for approved prescription drugs, with enforcement, march-in licensing, and DPA production tools to ensure access.
Official title: To establish fair prices for prescription drugs, and for other purposes.
Introduced May 26, 2026 by Brad Sherman · Last progress May 26, 2026
Creates a federal Prescription Drug Price Regulatory Commission to recommend and HHS to publish binding “fair prices” for approved prescription drugs beginning in 2027, and makes it illegal to sell drugs in the U.S. above those prices. The law authorizes civil and enforcement remedies (FTC enforcement, state parens patriae suits, private suits with treble damages), allows HHS to compel licensing of patents if a patent owner refuses to sell at the fair price or provide adequate supply, and enables the President to use Defense Production Act authorities to boost domestic production when supply is insufficient to meet fair-price access.